AKT1 and cancer: For example, at the pan-cancer level, U2AF1 mutations associate with sensitivity to multiple FLT3 inhibitors, such as AC220 (p = 8.3 × 10−8, CD = 2.5), Sorafenib (p = 3.04 × 10−6, CD = 2.8), Sunitinib (p = 5.6 × 10−5, CD = 2.5), and XL-184 (p = 1.3 × 10−4, CD = 1.9); PTEN mutations associate with sensitivity to an AKT inhibitor in COAD/READ (p = 3.5 × 10−6, CD = 2.4).